Significance of heat-shock protein (HSP) 90 expression in acute myeloid leukemia cells

Cell Stress and Chaperones

Volumn 13, Issue 3, 2008, Pages 357-364

  Flandrin, Pascale ^a,b   Guyotat, Denis ^b,c   Duval, Amélie ^a,b   Cornillon, Jérôme ^c   Tavernier, Emmanuelle ^c   Nadal, Nathalie ^a   Campos, Lydia ^a  

^a HÔPITAL NORD   (France)

^b CENTRE LÉON BÉRARD   (France)

^c Institut de Cancerologie de la Loire   (France)

Author keywords

Acute Myeloid Leukemia; Expression; HSP90

Indexed keywords

BUSULFAN; CD34 ANTIBODY; CYTARABINE; DAUNORUBICIN; HEAT SHOCK PROTEIN 90; IDARUBICIN; LOMUSTINE; MELPHALAN; MERCAPTOPURINE; METHOTREXATE; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN; PROTEIN BCL 2; PROTEIN KINASE B; PROTEIN P170; TANESPIMYCIN; UNCLASSIFIED DRUG; 17-(ALLYLAMINO)-17-DEMETHOXYGELDANAMYCIN; BENZOQUINONE DERIVATIVE; CD34 ANTIGEN; MACROCYCLIC LACTAM;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER SURVIVAL; CELL CULTURE; CELL GROWTH; CLINICAL EVALUATION; CLONOGENIC ASSAY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKEMIA CELL; LIQUID CULTURE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; STEM CELL; BONE MARROW CELL; CYTOLOGY; DRUG ANTAGONISM; GENETICS; METABOLISM; MIDDLE AGED; STATISTICS; SURVIVAL RATE;

ADULT; AGED; ANTIGENS, CD34; BENZOQUINONES; HSP90 HEAT-SHOCK PROTEINS; HUMANS; LACTAMS, MACROCYCLIC; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; MYELOID CELLS; STATISTICS AS TOPIC; SURVIVAL RATE;

EID: 53149084152     PISSN: 13558145     EISSN: 14661268     Source Type: Journal    
DOI: 10.1007/s12192-008-0035-3     Document Type: Article

References (38)

1. An WG, Schulte TW, Neckers LM (2000) The heat shock protein 90 antagonist geldanamycin alters chaperone association with p210bcr-abl and v-src proteins before their degradation by the proteasome. Cell Growth Differ 11:355-360 (Pubitemid 30619563)
2. Basso AD, Solit DB, Chiosis G et al (2002) Akt forms an intracellular complex with heat shock protein 90 (Hsp90) and Cdc37 and is destabilized by inhibitors of Hsp90 function. J Biol Chem 277:39858-39866 (Pubitemid 35190971)
3. Bradbury DA, Zhu YM, Russell NH (1997) BCL2 expression in acute myeloblastic leukaemia: relationship with autonomous growth and CD34 antigen expression. Leuk Lymphoma 24:221-228 (Pubitemid 27101594)
4. Campos L, Rouault JP, Sabido O et al (1993) High expression of BCL2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Blood 81:3091-3096 (Pubitemid 23162130)
5. Fujita N, Sato S, Ishida A, Tsuruo T (2002) Involvement of Hsp90 in signaling and stability of 3-phosphoinositide-dependent kinase-1. J Biol Chem 277:10346-10353
6. Fumo G, Akin C, Metcalfe DD, Neckers L (2004) 17-allylamino-17- demethoxygeldanamycin (17-AAG) is effective in down-regulating mutated, constitutively activated KIT protein in human mast cells. Blood 103:1078-1084 (Pubitemid 38129574)
7. George P, Bali P, Cohen P et al (2004) Co-treatment with 17-allylamino-demethoxygeldanamycin (17-AAG) and FLT3 kinase inhibitor PKC412 is highly effective against human AML cells with mutant FLT3. Cancer Res 64:3645-3652 (Pubitemid 38657944)
8. George P, Bali P, Annavarapu S et al (2005) Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT3. Blood 105:1768-1776 (Pubitemid 40223701)
9. Goetz MP, Toft DO, Ames MM, Erlichman C (2003) The Hsp90 chaperone complex as a novel target for cancer therapy. Ann Oncol 14:1169-1176 (Pubitemid 37039035)
10. Goetz MP, Toft D, Reid J et al (2005) A phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. J Clin Oncol 23:1078-1087 (Pubitemid 46202262)
11. Grenert JP, Sullivan WP, Fadden P et al (1997) The amino-terminal domain of heat shock protein 90 (hsp90) that binds geldanamycin is an ATP/ADP switch domain that regulates hsp90 conformation. J Biol Chem 272:23843-23850 (Pubitemid 27410964)
12. Harris NL, Jaffe ES, Diebold J (1999) World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting - Airlie House, Virginia, November 1997. J Clin Oncol 17:3835-3849
13. Hernandez MP, Sullivan WP, Toft DO (2002) The assembly and intermolecular properties of the hsp70-Hop-hsp90 molecular chaperone complex. J Biol Chem 277:38294-38304 (Pubitemid 35154683)
14. Hostein I, Robertson D, DiStefano F, Workman P, Clarke PA (2001) Inhibition of signal transduction by the Hsp90 inhibitor 17-allylamino-17- demethoxygeldanamycin results in cytostasis and apoptosis. Cancer Res 61:4003-4009 (Pubitemid 32720963)
15. Kamal A, Thao L, Sensintaffar J et al (2003) A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 425:407-410 (Pubitemid 37187270)
16. Kornblau SM, Womble M, Qiu YH, Jackson CE, Chen W, Konopleva M, Estey EH, Andreeff M (2006) Simultaneous activation of multiple signal transduction pathways confers poor prognosis in acute myelogenous leukemia. Blood 108:2358-2365 (Pubitemid 44497520)
17. Krutzig PO, Nolan GP (2003) Intracellular phosphor-protein staining techniques for flow cytometry: monitoring single cell signaling events. Cytometry A 55A:61-70
18. Kubota Y, Ohnishi H, Kitanaka A, Ishida T, Tanaka T (2004) Constitutive activation of PI3K is involved in the spontaneous proliferation of primary acute myeloid leukemia cells: direct evidence of PI3K activation. Leukemia 18:1438-1440 (Pubitemid 39136758)
19. Libura M, Asnafi V, Tu A et al (2003) FLT3 and MLL intragenic abnormalities in AML reflect a common category of genotoxic stress. Blood 102:2198-2204 (Pubitemid 37122399)
20. Lindquist S, Craig EA (1988) The heat-shock proteins. Annu Rev Genet 22:631-677 (Pubitemid 19156675)
21. Lowenberg B, van Putten WL, Touw IP, Delwel R, Santini V (1993) Autonomous proliferation of leukemic cells in vitro as a determinant of prognosis in adult acute myeloid leukemia. N Engl J Med 328:614-619 (Pubitemid 23065361)
22. Mesa RA, Loegering D, Powell HL et al (2005) Heat shock protein 90 inhibition sensitizes acute myelogenous leukemia cells to cytarabine. Blood 106:318-327 (Pubitemid 40967208)
23. Minami Y, Kiyoi H, Yamamoto Y, Yamamoto K, Ueda R, Saito H, Naoe T (2002) Selective apoptosis of tandemly duplicated FLT3-transformed leukemia cells by Hsp90 inhibitors. Leukemia 16:1535-1540
24. Nimmanapalli R, O'Bryan E, Kuhn D, Yamaguchi H, Wang HG, Bhalla KN (2003) Regulation of 17-AAG-induced apoptosis: role of BCL2, Bcl-XL, and Bax downstream of 17-AAG-mediated downregulation of Akt, Raf-1, and Src kinases. Blood 102:269-275 (Pubitemid 36759664)
25. Ochel HJ, Gademan G (2002) Heat-shock protein90: potential involvement in the pathogenesis of malignancy and pharmacological intervention. Onkologie 25:466-473 (Pubitemid 36160187)
26. Pratt WB, Toft DO (2003) Regulation of signaling protein function and trafficking by the hsp90/hsp70-based chaperone machinery. Exp Biol Med 22:111-133 (Pubitemid 36187918)
27. Radujkovic A, Schad M, Topaly J et al (2005) Synergistic activity of imatinib and 17-AAG in imatinib-resistant CML cells overexpressing BCR-ABL - inhibition of P-glycoprotein function by 17-AAG. Leukemia 19:1198-1206 (Pubitemid 40946004)
28. Rahmani M, Yu C, Dai Y, Reese E, Ahmed W, Dent P, Grant S (2003) Coadministration of the heat shock protein 90 antagonist 17-allylamino-17- demethoxygeldanamycin with suberoylanilide hydroxamic acid or sodium butyrate synergistically induces apoptosis in human leukemia cells. Cancer Res 63:8420-8427 (Pubitemid 37549498)
29. Sato S, Fujita N, Tsuruo T (2000) Modulation of Akt kinase activity by binding to Hsp90. Proc Natl Acad Sci USA 97:10832-10837
30. Schneider C, Sepp-Lorenzino L, Nimmesgern E et al (1996) Pharmacologic shifting of a balance between protein refolding and degradation mediated by Hsp90. Proc Natl Acad Sci USA 93:14536-14541 (Pubitemid 26419002)
31. Schultze TW, Neckers LM (1998) The benzoquinoneansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activity with geldanamycin. Cancer Chemother Pharmacol 42:273-279 (Pubitemid 28393843)
32. Stancato LF, Chow YH, Hutchison KA, Perdew GH, Jove R, Pratt WB (1993) Raf exists in a native heterocomplex with hsp90 and p50 that can be reconstituted in a cell-free system. J Biol Chem 268:21711-21716 (Pubitemid 23320668)
33. Sujobert P, Bardet V, Cornillet-Lefebvre P et al (2005) Essential role for the p110delta isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemia. Blood 106:1063-1066 (Pubitemid 41076455)
34. Thomas X, Campos L, Mounier C et al (2005) Expression of heat-shock proteins is associated with major adverse prognostic factors in acute myeloid leukemia. Leuk Res 29:1049-1058 (Pubitemid 40982599)
35. Xu Q, Simpson SE, Scialla TJ, Bagg A, Carroll M (2003) Survival of acute myeloid leukemia cells requires PI3 kinase activation. Blood 102:972-980 (Pubitemid 36917792)
36. Yao Q, Nishiushi R, Li Q, Kumar AR, Hudson WA, Kersey JH (2003) FLT3 expressing leukemias are selectively sensitive to inhibitors of the molecular chaperone heat shock protein 90 through destabilization of signal transduction-associated kinases. Clin Cancer Res 9:4483-4493 (Pubitemid 37248407)
37. Young JC, Moarefi I, Hartl FU (2001) HSP90: a specialized but essential protein-folding tool. J Biol Cell 154:267-273 (Pubitemid 34286138)
38. Yufu Y, Nishimura J, Nawata H (1992) High constitutive expression of heat shock protein 90 alpha in human acute leukemia cells. Leuk Res 16:597-605